Back to Search
DANIEL LAHERU, M.D.
Medical Oncology Physician
NPI: 1497796510Individual
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
D53070(MD)
Education
BAYLOR COLLEGE OF MEDICINE
Class of 1995
Research & Publications (20)
Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation.
PMID 18316569·Clin Cancer Res·2008
4-observational
A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer.
PMID 18765554·Clin Cancer Res·2008
3-trial
Development of a cytokine-modified allogeneic whole cell pancreatic cancer vaccine.
PMID 15542914·Methods Mol Med·2005
6-review
Immunotherapy for pancreatic cancer - science driving clinical progress.
PMID 15905855·Nat Rev Cancer·2005
6-review
Genes to vaccines for immunotherapy: how the molecular biology revolution has influenced cancer immunology.
PMID 16275985·Mol Cancer Ther·2005
6-review
Potential role of tumor vaccines in GI malignancies.
PMID 10736811·Oncology (Williston Park)·2000
6-review
Adjuvant chemoradiotherapy after pancreatic resection for invasive carcinoma associated with intraductal papillary mucinous neoplasm of the pancreas.
PMID 19647950·Int J Radiat Oncol Biol Phys·2010
8-other
SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer.
PMID 19584151·Clin Cancer Res·2009
8-other
Adjuvant chemoradiation versus surgery alone for adenocarcinoma of the ampulla of Vater.
PMID 19541379·Radiother Oncol·2009
4-observational
NCCN clinical practice guidelines in oncology: hepatobiliary cancers.
PMID 19406039·J Natl Compr Canc Netw·2009
6-review
[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy.
PMID 19380450·J Clin Oncol·2009
3-trial
DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.
PMID 19273710·J Clin Oncol·2009
8-other
Evaluating the impact of a single-day multidisciplinary clinic on the management of pancreatic cancer.
PMID 18461404·Ann Surg Oncol·2008
4-observational
Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors.
PMID 17429623·Cancer Chemother Pharmacol·2008
3-trial
Phase I study of troxacitabine administered by continuous infusion in subjects with advanced solid malignancies.
PMID 18245131·Ann Oncol·2008
3-trial
A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas.
PMID 18278438·Invest New Drugs·2008
3-trial
Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors.
PMID 18379785·Cancer Chemother Pharmacol·2008
3-trial
Determination of salirasib (S-trans,trans-farnesylthiosalicylic acid) in human plasma using liquid chromatography-tandem mass spectrometry.
PMID 18534927·J Chromatogr B Analyt Technol Biomed Life Sci·2008
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 600 N WOLFE ST
BALTIMORE, MD 21287 - Phone
- (410) 955-8964
Quick Facts
- NPI
- 1497796510
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile